Listen to this article Gaithersburg-based Novavax Inc. Tuesday announced its Nuvaxovid XBB.1.5 COVID-19 vaccine (NVX-CoV2601) ...

The emergency use listing is based on non-clinical data where the vaccine demonstrated immune responses against variants in ...

"The WHO Emergency Use Listing of our updated protein-based non-mRNA COVID-19 vaccine enables expedited regulatory approvals for its 194 member states and UN procurement agencies, such as UNICEF, ...

Erin Kissane, a co-founder of the COVID Tracking Project, rolled up her sleeve for the Novavax COVID-19 vaccine in ...

Novavax's updated COVID-19 vaccine is the only updated protein-based non-mRNA COVID-19 vaccine available in the European Union for individuals aged 12 and older Novavax is working closely with EU ...

A lot has changed with COVID-19 vaccines since they first debuted back in December 2020. We’ve seen a few hit the market, one ...

The single-target vaccine is aimed at the XBB.1.5 Omicron subvariant of the coronavirus, which was dominant in the U.S. for ...

The U.S Food and Drug Administration approved the first chikungunya vaccine- Ixchiq Ixchiq is administered as a single dose intra-muscularly for individuals over 18 years of age and older who are ...

University of Wisconsin School of Medicine and Public Health researchers are studying how a booster COVID-19 vaccine works ...

Novavax announced that Nuvaxovid XBB.1.5 COVID-19 Vaccine (NVX-CoV2601) has been granted Emergency Use Listing (EUL) by the ...